The Latest Breaking News from Pfizer

The Food and Drug Administration voiced concern Friday about myocarditis being potentially linked to the Novavax Covid-19 vaccine, just as experts are to weigh its use in the United States. The Novavax vaccine is already authorized in other countries, particularly in Europe. In the United States, an independent committee convened…

Social media users shared a range of false claims this week

For decades, anti-vaccine movements have generated and spread rumours that vaccines cause serious health problems. The rollout of COVID vaccines has provided new opportunities to spread misinformation.

The FDA and CDC will still need to authorize the shots.

Americans may soon get a new COVID-19 vaccine option — a more traditional kind of shot known as a protein vaccine

Children under five represent the only age group yet to have a vaccine approved for use

Myovant Sciences (NASDAQ: MYOV) and Pfizer (NASDAQ: PFE) received U.S.

Partners Pfizer, Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) urged the FDA to authorize three vaccine doses for children below five, the Wall Street Journal reports. The companies previously asserted that three doses of the shot were 80% effective at preventing symptomatic Covid-19 with robust immune response in children between six months to five years. After mixed results…

Severe undercounting undermines our efforts to ‘understand and get ahead of the virus’, researcher says after New York survey

WASHINGTON — Pfizer Inc. asked U.S. regulators to clear its COVID-19 vaccine for emergency use in children under age 5, an effort to extend protection against the virus to the country’s youngest.

Pfizer’s COVID-19 vaccine became available for children aged five to 11 in the UK in April 2022. Those aged 12 and up had already been eligible since 2021.